Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Capital Expenditures of $108000.0 for Q1 2026, down 60.73% on a QoQ basis from $275000.0 in Q4 2025, and up 217.65% year-over-year from $34000.0 in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Capital Expenditures history runs 10 years deep, the most recent figure standing at $108000.0 for Q1 2026.
- Quarterly Capital Expenditures rose 217.65% year-over-year to $108000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 86.72% YoY) and the FY2025 annual result came in at $1.2 million, down 87.57% from the prior year.
- Capital Expenditures was $108000.0 for Q1 2026 at Kiniksa Pharmaceuticals International, down from $275000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $9.5 million in Q4 2024 and bottomed at -$4.7 million in Q4 2023.
- A 5-year average of $386705.9 and a median of $34000.0 in 2025 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures plunged 14456.25% — and 2025, when it jumped 12552.17%.
- Kiniksa Pharmaceuticals International's Capital Expenditures stood at -$32000.0 in 2022, then plunged by 14456.25% to -$4.7 million in 2023, then soared by 304.68% to $9.5 million in 2024, then sank by 97.12% to $275000.0 in 2025, then sank by 60.73% to $108000.0 in 2026.
- Business Quant data shows KNSA's Capital Expenditures at $108000.0 in Q1 2026, $275000.0 in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | 108,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 108,000.00 |
| Mar 31, 2026 | 108,000.00 |
| Dec 31, 2025 | 275,000.00 |
| Dec 31, 2025 | 275,000.00 |
| Sep 30, 2025 | 2.91 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Mar 31, 2025 | 34,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 9.53 Mn |
| Dec 31, 2024 | 9.53 Mn |
| Sep 30, 2024 | 23,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Dec 31, 2023 | -4.66 Mn |
| Dec 31, 2023 | -4.66 Mn |